CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

EbselenWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1356 INM005 Wiki 0.71
drug1355 INC424 / Ruxolitinib Wiki 0.71
drug2122 Placebo Wiki 0.07

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.11
D007239 Infection NIH 0.07
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.

NCT04483973 Covid19 Coronavirus Coronavirus Infection Corona Virus Infection Drug: Ebselen Drug: Placebo
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respirator Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: Number of participants with treatment-related adverse events

Time: 30 days

Secondary Outcomes

Description: Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement

Measure: WHO Ordinal Scale

Time: 30 days

Description: Respiratory status assessed by degree of supplemental oxygen (e.g. mask oxygen, mechanical ventilation)

Measure: Degree of supplemental oxygen

Time: 30 days

Description: Peripheral oxygen saturation measured by pulse oximetry

Measure: Peripheral Oxygen Saturation (SpO2)

Time: 30 days

2 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.

NCT04484025 Covid19 Corona Virus Infection Coronavirus Coronavirus Infection Drug: Ebselen Drug: Placebo
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: Number of participants with treatment-related adverse events

Time: 30 days

Secondary Outcomes

Description: Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement

Measure: WHO Ordinal Scale

Time: 30 days

Description: Respiratory status assessed by degree of supplemental oxygen (e.g. mask oxygen, mechanical ventilation)

Measure: Degree of supplemental oxygen

Time: 30 days

Description: Peripheral oxygen saturation measured by pulse oximetry

Measure: Peripheral Oxygen Saturation (SpO2)

Time: 30 days

No related HPO nodes (Using clinical trials)